REC-617
Advanced solid tumors
REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.
Learn more on clinicaltrials.gov.
*Annual incidence for expected addressable patient subtypes. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Case study
The challenge:
1
2
The unique how:
The outcome:
Learn more about clinical trial at Recursion.
Clinical trials
